Oligonucleotide News and Research

RSS

Two-dimensional crystals from DNA origami tiles

DNA is more than just a carrier for our genetic information; DNA is also an outstanding nanoscale building material, as researchers led by Ned Seeman discovered thirty years ago. Seeman and his colleagues at the New York University (USA) have now used cross-shaped DNA tiles to produce an amazingly large grid structure that resembles woven fabric. As the researchers report in the journal Angewandte Chemie, these two-dimensional crystals attain dimensions of about 2×3 micrometers.

16 Nov 2010

RXi third quarter net loss increases to $4.1 million

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today reported its financial results for the third quarter ended September 30, 2010.

15 Nov 2010

Enzon data on LNA technology platform accepted for presentation at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today announced that data from preclinical studies of three investigational messenger RNA (mRNA) antagonists based on the locked nucleic acid (LNA) technology platform have been accepted for poster presentation at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics, which is being held November 16-19 in Berlin, Germany.

30 Oct 2010

Researchers develop morpholino oligonucleotides that can turn off specific genes

Researchers at North Carolina State University have found a way to "cage" genetic off switches in such a way that they can be activated when exposed to UV light. Their technology gives scientists a more precise way to control and study gene function in localized areas of developing organisms.

29 Oct 2010

Regulus receives $10M equity investment from sanofi-aventis

Regulus Therapeutics Inc. announced today that the Company has received a $10 million equity investment from sanofi-aventis in connection with the landmark alliance the two companies entered into on June 21, 2010. The equity investment by sanofi-aventis further strengthens the balance sheet of Regulus, and with this investment sanofi-aventis becomes the third investor in Regulus, along with its founding companies Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc..

29 Oct 2010

Antigene therapy uses light energy to silence gene activity: Review article

Antigene therapy is a promising new treatment strategy that uses a DNA-based drug to pinpoint light energy to a target gene shutting down its activity.

22 Oct 2010

Regulus present advancements in microRNA platform at Oligonucleotide Therapeutics Society meeting

Regulus Therapeutics Inc. announced today that advancements from its leading microRNA platform and product pipeline were presented at the "6th Annual Meeting of the Oligonucleotide Therapeutics Society" held October 20 - 23, 2010 in Dana Point, California.

22 Oct 2010

Idera announces IMO-3100 Phase 1 clinical trial results for autoimmune disease

Idera Pharmaceuticals, Inc. today announced results from its single-dose, dose-escalation Phase 1 clinical trial evaluating the safety and mechanism of action of IMO-3100, its lead Toll-like Receptor (TLR) 7 and TLR9 antagonist drug candidate for the treatment of autoimmune and inflammatory diseases.

22 Oct 2010

Bioniche's research scientists give presentations at Modern Vaccine and Adjuvant Formulation Conference

Bioniche Life Sciences Inc. a research-based, technology driven Canadian biopharmaceutical company, today announced that two of its senior research scientists gave presentations at the Modern Vaccine and Adjuvant Formulation Conference in Cannes, France this week.

18 Oct 2010

Prosensa receives £7.5M milestone payment in GSK2402968 Phase IIa trial for DMD

Prosensa, the Dutch biopharmaceutical company focusing on RNA modulating therapeutics, has announced that it received a £7.5m milestone payment from GlaxoSmithKline (GSK) as a result of achieving a data milestone in its Phase IIa open label extension trial of GSK2402968 (PRO051), being developed to treat Duchenne Muscular Dystrophy (DMD) under its agreement with GSK. The milestone payment was based upon achievement of a successful safety review, with no serious safety signals observed.

13 Oct 2010

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

Alnylam Pharmaceuticals, Inc.,a leading RNAi therapeutics company, announced today that it will make a total of 16 oral presentations at the American Chemical Society (ACS) Fall 2010 240th National Meeting & Exposition being held in Boston, Mass. from August 22-26, 2010.

24 Aug 2010

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today reported its financial results for the second quarter ended June 30, 2010.

11 Aug 2010

Alnylam second-quarter revenues increase to $26.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2010, and company highlights.

5 Aug 2010

Bio-Path commences dosing in Liposomal Grb-2 Phase I cancer study

Bio-Path Holdings, Inc.,, a biotechnology company with drug development operations in Houston, Texas, announced today that the first patient has been dosed in a Phase I study of its cancer drug candidate, Liposomal Grb-2 (L-Grb-2 or BP-100-1.01), in patients with Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL) or Myelodysplastic Syndrome (MDS).

30 Jul 2010

Affymetrix launches QuantiGene ViewRNA Assay formats

Affymetrix, Inc. today announced the launch of QuantiGene® ViewRNA Assay formats, which enable a new era of "in situ multiplex gene expression analysis" by allowing drug screening of native cells and advancing the pace of biomarker disease research and stem cell studies. These in situ assays enable researchers to visualize gene expression in individual cells at an unprecedented level of sensitivity and speed.

22 Jul 2010

TriLink, Affymetrix sign distribution and supply agreement

TriLink BioTechnologies, Inc. today announced that a multi-year distribution and supply agreement has been signed with California-based Affymetrix, Inc., a leading supplier of genetic analysis technologies. Under the terms of agreement, Affymetrix will use TriLink's high quality oligonucleotides in several of their kits.

19 Jul 2010

Nitto Denko, Quark collaborate to develop siRNA therapeutics for fibrotic diseases

Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.

15 Jul 2010

CSHL scientists reverse symptoms of Type III SMA using ASOs

The devastating, currently incurable motor-neuron disease spinal muscular atrophy might soon be treated with tiny, chemically modified pieces of RNA called antisense oligonucleotides.

13 Jul 2010

Idera announces issuance of patents for synthetic immune modulatory oligonucleotides targeted to TLRs

Idera Pharmaceuticals, Inc. today announced the issuance of patents covering compositions and methods of using its synthetic immune modulatory oligonucleotides targeted to Toll-like receptors (TLRs). The Company's intellectual property portfolio currently contains over 500 patents and patent applications worldwide and includes claims for TLR-targeted compounds, second-generation antisense chemistry, and oral delivery of certain oligonucleotides.

8 Jul 2010

Advanced Cancer Therapeutics secures $10M in investments

Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has secured $10 million in investments from high net-worth individuals and institutions. This round of investment, which closed six months ahead of the company's year-end goal, will provide ACT additional capital to continue its development and commercialization of potentially lifesaving therapeutics for cancer patients.

2 Jul 2010

Oligonucleotide News and Research

Two-dimensional crystals from DNA origami tiles

RXi third quarter net loss increases to $4.1 million

Enzon data on LNA technology platform accepted for presentation at EORTC-NCI-AACR Symposium

Researchers develop morpholino oligonucleotides that can turn off specific genes

Regulus receives $10M equity investment from sanofi-aventis

Antigene therapy uses light energy to silence gene activity: Review article

Regulus present advancements in microRNA platform at Oligonucleotide Therapeutics Society meeting

Idera announces IMO-3100 Phase 1 clinical trial results for autoimmune disease

Bioniche's research scientists give presentations at Modern Vaccine and Adjuvant Formulation Conference

Prosensa receives £7.5M milestone payment in GSK2402968 Phase IIa trial for DMD

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

Alnylam second-quarter revenues increase to $26.6 million

Bio-Path commences dosing in Liposomal Grb-2 Phase I cancer study

Affymetrix launches QuantiGene ViewRNA Assay formats

TriLink, Affymetrix sign distribution and supply agreement

Nitto Denko, Quark collaborate to develop siRNA therapeutics for fibrotic diseases

CSHL scientists reverse symptoms of Type III SMA using ASOs

Idera announces issuance of patents for synthetic immune modulatory oligonucleotides targeted to TLRs

Advanced Cancer Therapeutics secures $10M in investments

Industry Focus eBook - Protein Analysis (3rd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News